The economic costs of heart attack and chest pain (Acute Coronary Syndrome)

Derek Chew; David B. Brieger; Ren Tan; Jenny Coutts; Margaret Flaherty; Ineke Bleeker; Alex Brown; Graham Neville; Tony Arvidsson; Rohan Greenland; Andrew Boyden; Kim Goodman; Debbie White; Paul Middleton; Linda Soars; Deon Gouws; Paul Dale; Stuart Englund; Fiona Bailey

The economic costs of heart attack and chest pain (Acute Coronary Syndrome)

Derek Chew, David B. Brieger, Ren Tan, Jenny Coutts, Margaret Flaherty, Ineke Bleeker, Alex Brown, Graham Neville, Tony Arvidsson, Rohan Greenland, Andrew Boyden, Kim Goodman, Debbie White, Paul Middleton, Linda Soars, Deon Gouws, Paul Dale, Stuart Englund, Fiona Bailey

Research output: Book/Report › Commissioned report › peer-review

Abstract

Access Economics was commissioned by Eli Lilly to estimate the economic costs of Heart Attack and Chest Pain (Acute Coronary Syndrome-ACS) in Australia for 2009. In addition, an objective was to investigate current gaps in ACS treatment and clinical need, and highlight areas of treatment where further investment may result in significant benefits through a reduction in the burden of disease and improvements in efficiency and quality of care.

To estimate the economic costs of ACS, this study has used the comprehensive cost of illness framework used throughout the world. In brief, the study consists of the following sections:
■ epidemiology of ACS in Australia;
■ direct health care system costs associated with treatment;
■ indirect financial and economic costs;
■ value of the loss in health associated with morbidity and mortality; and
■ the future of ACS management in Australia.

Original language	English
Place of Publication	Australia
Publisher	Access Economics
Number of pages	86
Publication status	Published - Jun 2009

Cite this

@book{fe9942ee6b494466a0fb195b1046fdaa,

title = "The economic costs of heart attack and chest pain (Acute Coronary Syndrome)",

abstract = "Access Economics was commissioned by Eli Lilly to estimate the economic costs of Heart Attack and Chest Pain (Acute Coronary Syndrome-ACS) in Australia for 2009. In addition, an objective was to investigate current gaps in ACS treatment and clinical need, and highlight areas of treatment where further investment may result in significant benefits through a reduction in the burden of disease and improvements in efficiency and quality of care. To estimate the economic costs of ACS, this study has used the comprehensive cost of illness framework used throughout the world. In brief, the study consists of the following sections:■ epidemiology of ACS in Australia;■ direct health care system costs associated with treatment;■ indirect financial and economic costs;■ value of the loss in health associated with morbidity and mortality; and■ the future of ACS management in Australia.",

author = "Derek Chew and Brieger, {David B.} and Ren Tan and Jenny Coutts and Margaret Flaherty and Ineke Bleeker and Alex Brown and Graham Neville and Tony Arvidsson and Rohan Greenland and Andrew Boyden and Kim Goodman and Debbie White and Paul Middleton and Linda Soars and Deon Gouws and Paul Dale and Stuart Englund and Fiona Bailey",

year = "2009",

month = jun,

language = "English",

publisher = "Access Economics",

}

TY - BOOK

T1 - The economic costs of heart attack and chest pain (Acute Coronary Syndrome)

AU - Chew, Derek

AU - Brieger, David B.

AU - Tan, Ren

AU - Coutts, Jenny

AU - Flaherty, Margaret

AU - Bleeker, Ineke

AU - Brown, Alex

AU - Neville, Graham

AU - Arvidsson, Tony

AU - Greenland, Rohan

AU - Boyden, Andrew

AU - Goodman, Kim

AU - White, Debbie

AU - Middleton, Paul

AU - Soars, Linda

AU - Gouws, Deon

AU - Dale, Paul

AU - Englund, Stuart

AU - Bailey, Fiona

PY - 2009/6

Y1 - 2009/6

N2 - Access Economics was commissioned by Eli Lilly to estimate the economic costs of Heart Attack and Chest Pain (Acute Coronary Syndrome-ACS) in Australia for 2009. In addition, an objective was to investigate current gaps in ACS treatment and clinical need, and highlight areas of treatment where further investment may result in significant benefits through a reduction in the burden of disease and improvements in efficiency and quality of care. To estimate the economic costs of ACS, this study has used the comprehensive cost of illness framework used throughout the world. In brief, the study consists of the following sections:■ epidemiology of ACS in Australia;■ direct health care system costs associated with treatment;■ indirect financial and economic costs;■ value of the loss in health associated with morbidity and mortality; and■ the future of ACS management in Australia.

AB - Access Economics was commissioned by Eli Lilly to estimate the economic costs of Heart Attack and Chest Pain (Acute Coronary Syndrome-ACS) in Australia for 2009. In addition, an objective was to investigate current gaps in ACS treatment and clinical need, and highlight areas of treatment where further investment may result in significant benefits through a reduction in the burden of disease and improvements in efficiency and quality of care. To estimate the economic costs of ACS, this study has used the comprehensive cost of illness framework used throughout the world. In brief, the study consists of the following sections:■ epidemiology of ACS in Australia;■ direct health care system costs associated with treatment;■ indirect financial and economic costs;■ value of the loss in health associated with morbidity and mortality; and■ the future of ACS management in Australia.

UR - https://researchers.mq.edu.au/en/publications/the-economic-costs-of-heart-attack-and-chest-pain-acute-coronary-

M3 - Commissioned report

BT - The economic costs of heart attack and chest pain (Acute Coronary Syndrome)

PB - Access Economics

CY - Australia

ER -

The economic costs of heart attack and chest pain (Acute Coronary Syndrome)

Abstract

Other files and links

Fingerprint

Cite this